Prosperity7, a boutique investment consulting firm, led a $35m Series D2 funding round in Insilico Medicine, a clinical-stage end-to-end artificial intelligence-driven drug discovery company, with participation from Aramco Ventures. "The deepening application of AI and machine learning for drug discovery has demonstrated a transformative positive impact on the pharmaceutical industry and we are delighted to embark on this partnership with Insilico Medicine, a frontrunner in this innovation. Backed by the breadth of Aramco’s ecosystem across geographies and sectors, we look to support the company to scale up and expand its footprint globally, to drive biotechnology excellence, and to bring positive impact for greater wellbeing," Aysar Tayeb, Prosperity7 Ventures Executive Managing Director.